iShares Genomics Immunology and Healthcare ETF
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 6M SHOWN · NET +$36M OVER THIS RANGE
Money keeps arriving — +$7M of net buying over the past month, about 3.3% of the fund's asset base, while the price has returned +55.4% so far this year. At 0.47% a year it is not the cheapest way in — IWM runs the same ground at 0.19%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS TODAY’S MOVE · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | GSKGSK | 3.17% | $51.15 | +1.7% | ||
| 2 | TWSTTWIST BIOSCIENCE | 5.89% | $116.11 | -6.9% | ||
| 3 | RVMDREVOLUTION MEDICINES | 4.66% | $216.22 | +1.9% | ||
| 4 | MRNAMODERNA | 4.45% | $62.96 | -2.7% | ||
| 5 | REGNREGENERON PHARMACEUTICALS | 4.16% | $810.32 | +0.6% | ||
| 6 | INCYINCYTE | 3.95% | $123.42 | -0.0% | ||
| 7 | VRTXVERTEX PHARMACEUTICALS | 3.78% | $528.64 | +2.6% | ||
| 8 | MRKMERCK & CO | 3.69% | $135.12 | -0.6% | ||
| 9 | BNTXBIONTECH SE | 3.41% | $92.87 | +0.4% | ||
| 10 | EXELEXELIXIS | 3.25% | $53.11 | +1.5% | ||
| 11 | IDYAIDEAYA BIOSCIENCES | 3.13% | $37.49 | +2.3% | ||
| 12 | ROPROPER TECHNOLOGIES | 3.50% | $394.25 | +1.1% | ||
| 13 | IBRXIMMUNITYBIO | 3.07% | $7.73 | -2.4% | ||
| 14 | IOVAIOVANCE BIOTHERAPEUTICS | 2.83% | $7.03 | -1.2% | ||
| 15 | ABCLABCELLERA BIOLOGICS | 2.70% | $11.14 | -0.6% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 63| 1 week | +15.0% |
| 1 month | +24.2% |
| 3 months | +42.9% |
| 6 months | +40.2% |
| YTD | +55.4% |
| 1 year | — |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | — |
| 1 month | +$7M |
| 3 months | +$23M |
| YTD | +$36M |
| 1 year | +$36M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 5.9% of the book; the top ten carry 43%. Spread across 53+ names, it behaves like roughly 31 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| MRK MERCK & CO | $3M | $4M |
| RVMD REVOLUTION MEDICINES | $2M | $4M |
| MRNA MODERNA | $2M | $2M |
| VRTX VERTEX PHARMACEUTICALS | $1M | $2M |
| REGN REGENERON PHARMACEUTICALS | $1M | $1M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat IDNA on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| IJH iShares Core S&P Mid-Cap ETF | 0.05% | $128.4B | +$547M | -42bp on fee · 588× the assets · +$547M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $32.7B | +$104M | -43bp on fee · 150× the assets · +$104M in over the month | Head-to-head |
| IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF | 0.04% | $23.4B | +$520M | -43bp on fee · 107× the assets · +$520M in over the month | Head-to-head |
| IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF | 0.04% | $18.7B | +$312M | -43bp on fee · 86× the assets · +$312M in over the month | Head-to-head |
| IEFA iShares Core MSCI EAFE ETF | 0.07% | $195.3B | +$631M | -40bp on fee · 895× the assets · +$631M in over the month | Head-to-head |